Abstract
Disentangling direct and indirect genetic pathways underlying the intergenerational transmission of emotional problems could guide preventative strategies and further the understanding of the role of parental mental health in children’s outcomes. This study aimed to estimate the extent to which genetic pathways that are direct (via child genotype) and indirect (e.g., via parental phenotype) explain the well-established association between parent and child emotional problems. We leveraged data from seven European cohort studies with a combined population of Ntrios=15,475. Polygenic scores were calculated for parental and offspring neuroticism, as it represents a dispositional trait underlying emotional problems. Emotional problems in offspring were measured using validated scales across various developmental stages from early childhood to adulthood. We used neuroticism polygenic scores within a structural equation modelling framework to distinguish between direct genetic pathways from parental genotype to offspring outcome (acting through offspring genotype), and indirect genetic pathways (acting through parental phenotype and associated environment). Standard errors for direct genetic, indirect genetic and total effects were bootstrapped and meta-analyses pooled effect estimates at three developmental stages (childhood: 3-4 years, adolescence: 11-13 years, adulthood: 18+ years). We found evidence suggesting an indirect genetic pathway between mothers and child emotional problems during early childhood (pooled estimate, mean difference in standardised child emotional problems score per 1SD increase in maternal PGS for neuroticism=0.04, 95% CI: 0.01, 0.07). This association attenuated over child development, while direct genetic pathways strengthened. High attrition rates, measurement error and low variance explained by polygenic scores may have altered precision of the estimates, influencing the interpretation of the results. However, we provide the first multi-cohort study to provide evidence for an indirect genetic pathway from maternal neuroticism to early child emotional problems. This suggests that there are likely processes other than direct genetic pathways involved in the intergenerational transmission of emotional problems, highlighting the importance of timely support to prevent and reduce emotional issues in mothers as a preventative strategy for emotional difficulties.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This work was supported by European Research Council (ERC) under the European Union's Seventh Framework Programme (grant FP/2007-2013), European Research Council Grant Agreements (grants 758813; MHINT). HS, RW, DAL, NJT work in or are affiliated with a unit that receives funding from the University of Bristol and UK Medical Research Council () MC_UU_00032/05 and MC_UU_00032/06, MC_UU_00032/07). DAL is contribution to this study is supported by the European Research Council (Grant Agreement 101021566 ART-Health), GWAS data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgments.pdf). A. S. F. Kwong is supported by a Wellcome Early Career Award (Grant ref: 227063/Z/23/Z). Generation Scotland: Scottish Family Health Study was supported by the Chief Scientist Office (CZD/16/6) and the Scottish Funding Council (HR03006) and by the Wellcome Trust (104036/Z/14/Z). The POSEIDON study was supported by a grant of the Dietmar Hopp Foundation. The Norwegian Mother, Father and Child Cohort Study is supported by the Norwegian Ministry of Health and Care Services, and the Ministry of Education and Research. A.H. is supported by the Research Council of Norway (#274611, #336085 and #288083), the South-Eastern Norway Regional Health Authority (#2020022), and her contribution to this study is supported by the European Union's Horizon Europe Research and Innovation Programme (FAMILY, grant agreement No 101057529). Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union, or the other funding agents. Neither the European Union nor the granting authorities can be held responsible for them.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Each cohort received its own ethic approval to conduct the study. For example, ALSPAC study was approved by the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. European Research Council Grant Agreements (grant: MHINT) provided the ethic approval for combining the cohorts.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data from each individual cohort can be obtained through individual data request and will vary depending on the agreement with each cohort study. For example, ALSPAC data access is through a system of managed open access. Information on how to request access to ALSPAC data can be found on the ALSPAC website (http://www.bristol.ac.uk/alspac/researchers/access/). Access to data sets requires approval from The Regional Committee for Medical and Health Research Ethics in Norway and an agreement with MoBa. For the MCS, data access is free of charge and it is detailed here https://cls.ucl.ac.uk/data-access-training/data-access/.
